New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2014
07:03 EDTLLY, NVS, INCYIncyte sees FY14 Jakafi net product revenues $315M-$335M
The company (INCY) expects to receive a $60M milestone payment under its collaboration agreement with Novartis (NVS) when European Union pricing approval for Jakavi is received in a third major European country. Excluding any other potential milestones received under collaborations, the company expects revenues of approximately $13M from the amortization of the upfront payments received under its collaboration agreement with Lilly (LLY). The company expects interest expense to be approximately $48M, including a non-cash expense of $37M related to the amortization of the discount on the 2015 Notes, 2018 Notes and 2020 Notes.
News For INCY;NVS;LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
October 7, 2015
16:50 EDTNVSNovartis' Sandoz Canada launches PrSandoz Solifenacin on Canadian market
Sandoz Canada announced the launch of a new drug on the Canadian market, PrSandoz Solifenacin, which is used in reducing urinary urgency, frequency and incontinence. PrSandoz Solifenacin is a generic equivalent to the product Vesikur marketed in Canada under the name PrVesicare. This generic drug is available immediately on the Canadian market. Sandoz Canada is part of Sandoz International GmbH, the world's second largest producer of generic drugs and a company of the Swiss multinational corporation, Novartis (NVS).
07:34 EDTNVSAlliance for Regenerative Medicine to hold a meeting
Stem Cell Meeting on the Mesa is being held in La Jolla, California on October 7-9.
07:23 EDTNVSEuropean Committee Treatment & Research in Multiple Sclerosis holds meeting
Subscribe for More Information
October 6, 2015
13:32 EDTLLY, NVSBiotechs plummet with TPP seen as industry negative
Biotechs are falling intraday after reports that the Trans-Pacific Partnership, or TPP, has language that the exclusivity period for bioligics, or drugs derived from a biological sources, would be eight years, less than the twelve years it is currently in the United States. WHAT'S NOTABLE: In the U.S., biologics are protected from competition by follow-on products for twelve years from the time they are first granted marketing approval by the U.S. Food and Drug Administration, a protection that is distinct from patent protection. Recent reports on the TPP suggest that the protection will last five years with an additional safety monitoring period of up to three years before a biosimilar can be registered, which would effectively be an eight year exclusivity period. ANALYST REACTION: Piper Jaffray analyst Joshua Schimmer, however, said the development is a "step forward," especially since it does not overrule the 12 years' exclusivity for the drugs in the U.S. While the sector asked for twelve years' exclusivity to match the U.S., eight years is a "reasonable compromise," the analyst argued. His top picks were Alexion (ALXN), Celgene (CELG), and Amgen (AMGN) in the large-cap space, GW Pharmaceuticals (GWPH) and bluebird bio (BLUE) among mid-caps, and Flex Pharma (FLKS), Lion Biotechnologies (LBIO), Otonomy (OTIC), and Ignyta (RXDX) in the small-cap sector. Further, Schimmer stated that more names look "increasingly compelling" amid the selloff. NOTABLE DECLINERS: Alexion is lower by 2.53%, Celgene is down 4.32%, Amgen is declining 1.91%, Biogen (BIIB) is down 3.4%, and Gilead Sciences (GILD) is falling 2.22%. STOCKS TO WATCH: Other publicly traded companies in the pharmaceutical space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
05:23 EDTLLYEli Lilly, Adocia initiate Phase 1b study of BioChaperone Lispro
Subscribe for More Information
October 5, 2015
05:25 EDTNVSAlcon receives FDA approval for AcrySof IQ Aspheric IOL
Subscribe for More Information
October 2, 2015
07:31 EDTINCYIncyte to present new data on immuno-oncology portfolio at SITC
Subscribe for More Information
October 1, 2015
11:06 EDTNVSXOMA price target raised to $1.50 from $1 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for XOMA (XOMA) to $1.50 after the company partnered a preclinical TGF-beta antibody with Novartis (NVS) for $37M upfront and up to $480M in milestones. The payment brings XOMA's pro forma cash to $88M, enabling the company to advance its endocrine antibody pipeline, including lead candidate XOMA 358 for hyperinsulinism disorders, Tenthoff tells investors in a research note. The analyst keeps a Neutral rating on the name. The stock is up 20c to 95c in early trading.
10:37 EDTLLYBofA/Merrill's Top 10 US Ideas for Q4 2015
Subscribe for More Information
07:37 EDTNVSXOMA announces agreement for anti-TGFb program with Novartis
Subscribe for More Information
07:31 EDTINCYLeerink to hold a roundtable
Subscribe for More Information
September 30, 2015
17:04 EDTNVSNovartis says results of Phase 3 study of secukinumab met endpoints
Subscribe for More Information
08:30 EDTINCYIncyte to join Nasdaq-100 Index beginning Oct. 7, to replace Altera
Nasdaq yesterday announced that Incyte Corporation (INCY), will become a component of the NASDAQ-100 Index and the NASDAQ-100 Equal Weighted Index prior to market open on Wednesday, October 7, 2015. Incyte Corporation will replace Altera Corporation (ALTR). Incyte Corporation is headquartered in Palo Alto, California, and has a market capitalization of approximately $19B.
06:16 EDTLLYEli Lilly volatility at 52-week highs
Subscribe for More Information
05:41 EDTLLYEli Lilly, Adocia initiate new Phase 1b study evaluating BioChaperone Lispro
Subscribe for More Information
September 29, 2015
12:35 EDTNVSPerrigo shareholders pressure company to explore sale, Reuters says
Certain Perrigo (PRGO) shareholders have requested that company explore a sale, hoping for an alternative to Mylan's (MYL) approximately $25B hostile bid, Reuters reports, citing people familiar with the matter. The pressure represents a challenge to Perrigo's defense strategy, the report says. Some of the company's shareholders view Novartis (NVS), Sanofi (SNY), Procter & Gamble (PG), and Colgate-Palmolive (CL) as potential suitors, the report says. Reference Link
09:27 EDTLLYOn The Fly: Pre-market Movers
HIGHER: Yahoo (YHOO), up 4.5% after the company's board authorized the company to continue to pursue its spin-off of Aabaco Holdings, a newly formed independent registered investment company that will hold all of Yahoo's remaining holdings in Alibaba Group (BABA)... Phoenix Companies (PNX), up 164% after Nassau Reinsurance agreed to acquire Phoenix for $37.50 per share in cash... McDonald's (MCD), up 1.4% after the stock was upgraded to Outperform at Credit Suisse... Johnson & Johnson (JNJ), up 1% following upgrade at Deutsche Bank. LOWER: Esperion (ESPR), down 29% after reporting that the FDA has encouraged the company to initiate a cardiovascular outcomes trial promptly since any concern regarding the benefit/risk assessment of ETC-1002 could necessitate a completed cardiovascular outcomes trial before approval... Solera (SLH), down 2% after IHS (IHS) said on its earnings call that it is not pursuing an acquisition of the company, as previouly indicated in media reports... Zosano (ZSAN), down 54% after the company announced that it would discontinue its ZP-PTH agreement with Eli Lilly (LLY).
08:46 EDTNVSNoven reports final decisions in IPRs challenging Novartis' Exelon patch patents
Subscribe for More Information
08:43 EDTLLYZosano Pharma price target lowered to $11 from $20 at Roth Capital
Roth Capital cut its price target on Zosano (ZSAN) after the company announced that it would discontinue its ZP-PTH agreement with Eli Lilly (LLY) in order to focus on a one time per week program. The firm expects Zosano's shares to drop significantly today, but it continues to expect the company's other programs to generate positive data. It keeps a Buy rating on the shares.
06:47 EDTLLY, INCYEli Lilly and Incyte's baricitinib Phase 3 study met primary objective
Subscribe for More Information
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use